Wockhardt (WOCKPHARMA) Q2 24/25 earnings summary

Executive summary

• Standalone and consolidated financial results for the quarter and six months ended September 30, 2024, were reviewed and approved by the Board and subjected to limited review by statutory auditors.

• The company operates exclusively in the pharmaceutical segment, with a global presence through multiple subsidiaries.

Financial highlights

• Standalone revenue from operations for Q2 FY25 was ₹370 crore, up from ₹260 crore in Q2 FY24; total income was ₹381 crore.

• Standalone net loss after tax for Q2 FY25 was ₹36 crore, compared to a net loss of ₹107 crore in Q1 FY25 and ₹30 crore in Q2 FY24.

• Consolidated revenue from operations for Q2 FY25 was ₹809 crore, compared to ₹753 crore in Q2 FY24; total income was ₹818 crore.

• Consolidated net loss after tax for Q2 FY25 was ₹16 crore, compared to a net loss of ₹73 crore in Q2 FY24.

• Earnings per share (EPS) for Q2 FY25 (consolidated) was ₹(1.47), compared to ₹(5.37) in Q2 FY24.

Outlook and guidance

• No explicit forward-looking guidance provided, but recent capital raise and improved loss position indicate focus on strengthening the balance sheet and operational recovery.